Don’t use Promacta for patients with chronic liver disease

On May 2, the U.S. Food and Drug Administration and GlaxoSmithKline reminded health professionals not to use Promacta (eltromobopag) for the treatment of thrombocytopenia in patients with chronic liver disease. Read more at

Related Articles:

Leave a Reply

Your email address will not be published. Required fields are marked *